To determine the effect of Scriptaid, a compound that can replicate aspects of the exercise adaptive response through disruption of the class IIa histone deacetylase (HDAC) corepressor complex, on muscle insulin action in obesity.
impact on aspects of systemic metabolism. 1 First-line pharmacological interventions used to treat metabolic diseases have only limited direct effects on normalizing skeletal muscle metabolism. 4, 5 Exercise is one intervention that enhances these aspects of muscle metabolism and has additional whole-body benefits, such as increasing energy expenditure and lipid utilization. 6 New pharmacological strategies are needed to enhance muscle metabolism in patient populations that cannot exercise or have low exercise adherence. It has been proposed that discovery of pharmacological interventions that replicate aspects of the adaptive response to exercise could be an important step in developing more efficacious treatments of metabolic diseases. 7, 8 We recently validated the class IIa histone deacetylases (HDACs)
as drug targets to replicate aspects of the adaptive response to exercise.
Furthermore, we identified the hydroxamic acid-based compound Scriptaid as a drug that induced exercise-like effects, not through inhibition of HDAC activity, but through disruption of the class IIa HDAC corepressor complex. 9 Class IIa HDACs are transcriptional repressors of myocyte enhancer factor 2 (MEF2) transcription factors. 10 Unlike class I HDACs, class IIa HDACs do not possess intrinsic HDAC activity because of a key amino acid substitution in their active site. 11 Instead, their repressive activity is related to the recruitment of a corepressor complex that contains N-Cor/SMRT and HDAC3. 12 We have previously observed that class IIa HDACs are exported from the nucleus in skeletal muscle during exercise, thereby disrupting the class IIa corepressor complex, which was associated with the expression of MEF2-dependent genes. 13, 14 More recently, we showed that disruption of the class IIa HDAC corepressor complex, through either genetic means or via Scriptaid, relieved MEF2 repression, increased the expression of genes involved in oxidative metabolism and increased oxidative flux in skeletal muscle. 9 Furthermore, chronic Scriptaid treatment in lean mice increased exercise performance, increased whole-body energy expenditure and lipid oxidation and reduced blood glucose and lipids; 9 however, whether Scriptaid has any therapeutic benefit for metabolic diseases such as obesity and type 2 diabetes is unknown. The aim of the present study, therefore, was to examine the effect of Scriptaid on muscle insulin action in diet-induced obese mice. As exercise is also known to have positive effects on cardiac muscle function, a secondary aim was to examine the effect of Scriptaid on cardiac morphology and function.
| MATERIALS AND METHODS

| Animal studies
All experimental procedures were approved by the Deakin University Animal Welfare Committee, which is subject to the Australian Code for the 16 Five days later, mice were humanely killed and blood was drawn by cardiac puncture and collected into tubes containing heparin, followed by centrifugation at 4 C at 10 000 g for 10 minutes and plasma was collected. Tissues were collected, weighed, snapfrozen in liquid nitrogen and stored at −80 C until analysis of gene and protein expression and lipid levels, while a portion of the left ventricle was fixed for histological analysis.
| Plasma analyses
Plasma insulin throughout the i.p. GTT was assessed using a Mouse
Insulin ELISA kit (ALPCO Diagnostics, Salem, New Hampshire). Lipids were extracted from~10 μL of plasma obtained from cardiac puncture using 20 volumes of chloroform:methanol (2:1) in a single-phase extraction process, recovering all lipids in a single phase suitable for liquid chromatography-mass spectrometry analysis, as previously described. 
| Tissue analyses
Gene expression profiling was performed by extracting RNA from tissues using RNA columns and reverse transcribing RNA to cDNA, as previously described. 18 Real-time RT-PCR was performed using
Sybr green detection, and log-transformed CT values were normalized to cDNA concentration, determined by Oligreen (Life Technologies, Carlsbad, California), to determine relative gene expression levels. Amplification of mRNA was performed using primers that we have published previously. 16, 19 To determine protein expression, tissues were homogenized, protein determined using the BCA assay and immunoblotting with primary antibodies for HSL, pS473 Akt, p-pan protein kinase C (PKC; Cell Signaling Technology, Danvers, Massachusetts) CPT-1b and tubulin (Sigma-Aldrich, St
Louis, Missouri) was performed as previously described. 18 Ex vivo glucose uptake and fatty acid assays were performed as previously described, 20 in the EDL and TA muscles, respectively. Briefly, basal or insulin-stimulated ( Muscle and liver lipids were extracted from~10 mg of tissue, and mass spectrometer determination of lipids was performed as previously described. 21 The size of cardiomyocytes from the left ventricle was determined from haematoxylin and eosin stained sections, as previously described. 16 
| Statistical analyses
All data are expressed as mean AE standard error of the mean (s.e.m.).
Data normality was assessed using SPSS statistical software. For normally distributed data, differences between groups were assessed using a t-test, and 1-, 2-and 3-way analysis of variance, as appropriate using Minitab statistical software. Specific differences between groups were identified using Tukey post hoc tests. For non-normally distributed data, non-parametric tests were used, with SPSS statistical software. Differences were considered statistically significant for P values < .05.
| RESULTS
| Effect of Scriptaid on whole-body energy balance
Male C57BL6 mice were rendered obese through 12 weeks of highfat feeding before administration of vehicle or Scriptaid for a period of 4 weeks via daily i.p. injection. Scriptaid had no effect on body mass ( Figure 1A ), lean mass ( Figure S1A ) or fat mass ( Figure S1B ).
Consistent with our previous observations with this drug in lean mice, Scriptaid administration increased whole-body energy expenditure in the light phase ( Figure 1B) , which was associated with increased lipid oxidation ( Figure 1C ). There was no change in carbohydrate oxidation ( Figure S1C ) or voluntary activity levels ( Figure S1D ) in Scriptaidtreated mice. Similar to our findings in chow-fed mice, Scriptaid administration resulted in a small but significant increase in food intake ( Figure 1D ). These data show that, similarly to our previous findings in lean mice, treatment of obese mice with Scriptaid increased energy expenditure, supported by an increase in lipid oxidation, but did not alter body weight.
| Scriptaid enhanced insulin action, increased the expression of metabolic genes, increased fatty acid oxidation and reduced lipids in skeletal muscle
The effect of Scriptaid on skeletal muscle in obese mice was examined. Consistent with obesity-induced insulin resistance, insulin did not significantly increase ex vivo 2-deoxyglucose uptake by EDL muscles from vehicle-treated mice (Figure 2A ). By contrast, insulin significantly increased 2-deoxyglucose uptake by EDL muscles from Scriptaid-treated mice (Figure 2A ). Scriptaid did not increase GLUT4
or Syntaxin 4 protein levels ( Figure S2A ), suggesting mechanisms other than enhanced capacity of the glucose transport system were contributing to this effect. In an effort to explain this effect on skeletal muscle insulin action, we examined the effect of Scriptaid on exercise-like adaptive responses in these mice. Our previous studies have shown that Scriptaid increases a number of exercise-responsive genes involved in lipid metabolism in skeletal muscle. 9 Similarly, Scriptaid increased the expression of Hsl, Pdk4, Cpt-1b, Sdhb, Atp5d and
Pgc-1α ( Figure 2B ). Scriptaid did not significantly increase HSL protein, but did increase the protein levels of CPT-1β ( Figure 2C ). Ex vivo fatty acid oxidation assays were performed in the TA muscle, and complete oxidation of palmitate to CO 2 was increased in Scriptaidadministered mice ( Figure 2D ), while acid soluble metabolites that are associated with incomplete fatty acid oxidation and insulin resistance 22 were reduced ( Figure S2B ). This was associated with a reduction in skeletal muscle triglycerides (TG; Figure 2E ) and diacylglyceride (DG; Figure 2F ). There was no change in muscle ceramide ( Figure S2C ). As certain DG species have been associated with insulin resistance, 23 these were assessed using a targeted lipidomics approach. A number of DG species incorporating 16 and 18 carbon fatty acids were reduced in Scriptaid-treated mice ( Figure 2G ). As
DGs are thought to induce skeletal muscle insulin resistance via PKC activation that ultimately inhibits insulin signalling, 24 pan-PKC phosphorylation was assessed. There was no difference in PKC phosphorylation between vehicle-and Scriptaid-treated mice ( Figure S2D ).
Furthermore, insulin-stimulated Akt phosphorylation was not different between vehicle-and Scriptaid-treated mice ( Figure S2E ), consistent with the idea that impairments in insulin signalling are not obligatory for insulin resistance. 25 Nonetheless, these data show that Scriptaid increases skeletal muscle insulin sensitivity, metabolic gene expression and fatty acid oxidation and reduces lipids in skeletal muscle of obese mice.
Although not a primary aim of the study, whole-body glucose homeostasis was next assessed in these mice. Scriptaid had no effect on glucose tolerance during an i.p. GTT ( Figure S3A ). Insulin levels throughout the i.p. GTT were not different between vehicle-and Scriptaid-treated mice ( Figure S3B ). Blood glucose levels during the ITT were also not different between treatment groups ( Figure S3C ).
Unlike our previous observations in lean mice, 9 plasma lipids were not altered in obese mice treated with Scriptaid ( Figure S3D ). We also assessed the effects of Scriptaid on aspects of liver metabolism.
Scriptaid treatment had no effect on liver weight (data not shown) or gluconeogenic and lipogenic gene expression ( Figure S3E ). Furthermore, Scriptaid had no effect on hepatic TGs ( Figure S3F ), DGs ( Figure S3G ) or ceramides ( Figure S3H ).
| Scriptaid reduces heart weight and increases cardiac expression of metabolic genes in obesity
Cardiomyopathy is common in obesity and is characterized by increased heart size and contractile dysfunction, which can occur independently of hypertension. 26 Indeed, cardiovascular disease is the major cause of morbidity and mortality in obesity. Many current drugs used to treat metabolic diseases have negligible effects on cardiovascular outcomes and obesity-induced heart failure in particular, which has led to calls for more in-depth evaluation of cardiovascular function in pre-clinical drug discovery and clinical trials for new metabolic disease drugs. 27 Because exercise is known to have positive effects on cardiac function and we have observed an increase in histone acetylation after acute Scriptaid administration, 9 we evaluated the effect of Scriptaid on obesity-induced cardiomyopathy. Scriptaid reduced absolute heart weight ( Figure 3A) , and the heart weight to tibia length ratio ( Figure 3B) , suggesting that the effect of Scriptaid was not attributable to altered body size. Indeed, Scriptaid reduced the diameter of cardiomyocytes ( Figure S4A ), assessed from heart sections stained with haematoxylin and eosin. The loss of the class IIa
HDACs throughout development predisposes to cardiac hypertrophy through lost repression of foetal cardiac genes. 28 Gene expression analysis confirmed that Scriptaid did not reactivate components of the foetal gene programme, such as ANF, BNP and β-MHC ( Figure S4B) ; however, as impaired energy metabolism is thought to be a primary driver of cardiac hypertrophy in obesity, 29 Figure 3C ). These data show that Scriptaid reduces heart weight and enhances the expression of genes involved in lipid metabolism in the heart. 
| Scriptaid enhances cardiac function and morphology in obesity
To determine whether the reduction in heart weight and increased (Table 1) . Scriptaid administration enhanced the E:A ratio ( Figure 4B ), a key measure of diastolic function that represents the ratio between early and late filling of the atria. Scriptaid also enhanced measures of systolic function, including reduced ejection time ( Figure 4C ) and increased ejection fraction ( Figure 4D ) and fractional shortening ( Figure 4E ).
These data show that Scriptaid enhances many indices of obesityinduced cardiomyopathy. This represents a further therapeutic benefit of class IIa HDAC corepressor disruption in metabolic disease states.
| DISCUSSION
Current drugs used to treat metabolic diseases have limited efficacy in directly normalizing skeletal muscle insulin sensitivity and cardiac function; however, exercise is an effective approach to enhance these aspects of metabolic disease pathology. Our recent finding that Scriptaid can recapitulate some aspects of the exercise adaptive response, through disruption of the class IIa HDAC FIGURE 3 Scriptaid reduces heart weight and increases cardiac expression of metabolic genes in obesity. A, Heart weight; B, heart weight/tibia length and C, expression of metabolic genes in mice administered vehicle (5% DMSO in PBS) or Scriptaid (1 mg/kg body weight) via daily i.p. injection for 4 weeks (n = 8-10/group). Data represented as mean AE s.e.m. *Denotes significantly different from vehicle-treated mice (P < .05). Another important observation from the present study was that Scriptaid was able to reduce cardiac hypertrophy and improve cardiac function in obese mice. These findings are significant as cardiovascular disease accounts for~65% of deaths in obese and diabetic patients. 30 Current pharmacological approaches for metabolic diseases have limited or no efficacy against the development of heart disease. 31 Indeed, a limitation to a number of metabolic disease therapies has been adverse cardiovascular events 32 ; therefore, the discovery of a therapeutic approach that not only enhances muscle metabolism, but also normalizes cardiac structure and function in obesity is a significant advance that could have a great impact on patient treatment and mortality. Ablation of class IIa HDAC family members throughout development has been associated with a predisposition for stress-induced cardiac hypertrophy, largely through re-activation of the foetal gene programme 33, 34 ;
however, HDAC inhibitor use in adult stress models suggests that
HDACs have divergent roles in hypertrophy in the developing and adult heart. 35, 36 Reinforcing this view, Scriptaid had no effect on the expression of cardiac foetal genes such as ANF, BNP and β-MHC in the present study. Impaired energetics has been linked to the cardiomyopathy observed in obesity and type 2 diabetes 37 and Scriptaid enhanced the expression of a number of genes involved in fatty acid oxidation in the heart, just as it did in skeletal muscle. Additional studies will be required to determine whether Scriptaid enhances insulin action and reduces lipids in the heart.
Despite enhancing skeletal muscle insulin action, Scriptaid had no effect on glucose tolerance or whole-body insulin action in obese mice. These data are consistent with a number of studies in genetically modified animals, showing that alterations in skeletal muscle insulin action have limited impact on these tests. For example, muscle insulin receptor knockout mice have impaired muscle insulin action, but no defect in whole-body glucose or insulin tolerance. 38 Similarly, muscle-specific ablation of glycogen synthase impaired muscle insulin action, but enhanced whole-body glucose tolerance. 39 These data are consistent with the liver as being the primary tissue influencing glycaemia during these tolerance tests in mice. 40 Although we found that Scriptaid did not alter hepatic gluconeogenic and lipogenic gene expression or hepatic lipids, we cannot exclude the possibility that Scriptaid has deleterious effects on hepatic insulin action or glucose effectiveness. An area of future research will be to determine whether compounds that enhance muscle metabolism, such as Scriptaid, enhance the clinical efficacy of existing metabolic disease drugs when used in combination. A further application of this therapeutic approach could be to enhance exercise tolerance in patients who cannot or will not exercise, thereby allowing patients to benefit from the wide-ranging health benefits of exercise.
In conclusion, the present study reports that Scriptaid, which disrupts the class IIa corepressor complex in skeletal muscle, enhances muscle insulin action and cardiac function in obesity. As current therapeutic approaches have limited efficacy in normalizing these aspects of metabolic disease, targeting the class IIa corepressor complex could provide a more holistic approach to combating these diseases. 
